Cargando…
Biologics as countermeasures for acute radiation syndrome: where are we now?
Despite significant scientific advances toward the development of a safe, nontoxic and effective radiation countermeasure for acute radiation syndrome (ARS) over the past six decades, no drug has been approved by the US FDA. Several biologics are currently under development as radiation countermeasu...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Informa Healthcare
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720033/ https://www.ncbi.nlm.nih.gov/pubmed/25416452 http://dx.doi.org/10.1517/14712598.2015.986453 |